PLGA Nanoparticles Co-encapsulating NY-ESO-1 Peptides and IMM60 Induce Robust CD8 and CD4 T Cell and B Cell Responses

Tumor-specific neoantigens can be highly immunogenic, but their identification for each patient and the production of personalized cancer vaccines can be time-consuming and prohibitively expensive. In contrast, tumor-associated antigens are widely expressed and suitable as an off the shelf immunothe...

Повний опис

Збережено в:

Бібліографічні деталі
Автори:	Yusuf Dölen, Uzi Gileadi, Ji-Li Chen, Michael Valente, Jeroen H. A. Creemers, Eric A. W. Van Dinther, N. Koen van Riessen, Eliezer Jäger, Martin Hruby, Vincenzo Cerundolo, Mustafa Diken, Carl G. Figdor, I. Jolanda M. de Vries
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Frontiers Media S.A. 2021-02-01
Серія:	Frontiers in Immunology
Предмети:	NY-ESO-1 iNKT cell B cell epitope peptide vaccine IMM60 PLGA nanoparticle
Онлайн доступ:	https://www.frontiersin.org/articles/10.3389/fimmu.2021.641703/full
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!

PLGA Nanoparticles Co-encapsulating NY-ESO-1 Peptides and IMM60 Induce Robust CD8 and CD4 T Cell and B Cell Responses

Схожі ресурси